Suppr超能文献

消痞方对三阴性乳腺癌CXCL1及选定结局的调节作用:一项随机对照临床试验

Modulatory Effects of XIAOPI Formula on CXCL1 and Selected Outcomes in Triple-Negative Breast Cancer: A Randomized Controlled Clinical Trial.

作者信息

Guo Li, Hong Shi-Cui, Wang Xuan, Wang Sheng-Qi, Wang Neng, Wei Xiao-Qing, Situ Hong-Lin, Wang Zhi-Yu

机构信息

Breast Disease Specialist Hospital of Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, 510120, People's Republic of China.

The Second Clinical College of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, 510120, People's Republic of China.

出版信息

Breast Cancer (Dove Med Press). 2024 May 31;16:289-303. doi: 10.2147/BCTT.S462296. eCollection 2024.

Abstract

BACKGROUND

Triple-negative breast cancer (TNBC) is the most aggressive malignancy. Psychological distress and elevated CXCL1 level have been reported to be closely associated with the poor prognosis and quality of life of patients with TNBC. In preclinical studies using xenograft mouse models, XIAOPI formula, a nationally approved drug prescribed to patients at high risk for breast cancer, inhibited CXCL1 expression and improved survival. Traditional Chinese medicine has unique advantages in improving patients' emotional disorders and quality of life. However, the impact of XIAOPI formula on the serum level of CXCL1, psychological distress, and quality of life among patients with TNBC is currently unknown.

METHODS

In this study, we designed a randomized, double-blind, placebo-controlled trial. Patients with TNBC were randomly assigned to receive either the XIAOPI formula or a placebo for three months. The primary outcomes include serum CXCL1 expression, Self-Rating Anxiety Scale (SAS), and the Self-Rating Depression Scale (SDS). Secondary outcomes included the Pittsburgh Sleep Quality Index (PSQI) and the Functional Assessment of Cancer Therapy-Breast (FACT-B).

RESULTS

A total of 60 patients with TNBC were enrolled in the investigation. The results showed that the XIAOPI formula significantly decreased CXCL1 expression compared with the control group. Moreover, in comparison to the placebo, the XIAOPI formula increased FACT-B scores while decreasing SDS, SAS, and PSQI scores.

CONCLUSION

In patients with TNBC, XIAOPI formula may be effective in reducing CXCL1 levels, enhancing psychological well-being, and quality of life. While our research offers a natural alternative therapy that may enhance the prognosis of TNBC, future validation of its therapeutic effects will require large-scale, long-term clinical trials.

CLINICAL REGISTRATION NUMBER

Registration website: www.chictr.org.cn, Registration date: 2018-1-19, Registration number: ChiCTR1800014535.

摘要

背景

三阴性乳腺癌(TNBC)是最具侵袭性的恶性肿瘤。据报道,心理困扰和CXCL1水平升高与TNBC患者的不良预后和生活质量密切相关。在使用异种移植小鼠模型的临床前研究中,消痞方(一种国家批准用于乳腺癌高危患者的药物)可抑制CXCL1表达并提高生存率。中药在改善患者情绪障碍和生活质量方面具有独特优势。然而,消痞方对TNBC患者血清CXCL1水平、心理困扰和生活质量的影响目前尚不清楚。

方法

在本研究中,我们设计了一项随机、双盲、安慰剂对照试验。TNBC患者被随机分配接受消痞方或安慰剂治疗三个月。主要结局包括血清CXCL1表达、自评焦虑量表(SAS)和自评抑郁量表(SDS)。次要结局包括匹兹堡睡眠质量指数(PSQI)和癌症治疗功能评估-乳腺癌(FACT-B)。

结果

共有60例TNBC患者参与了本研究。结果显示,与对照组相比,消痞方可显著降低CXCL1表达。此外,与安慰剂相比,消痞方提高了FACT-B评分,同时降低了SDS、SAS和PSQI评分。

结论

对于TNBC患者,消痞方可能有效降低CXCL1水平,改善心理健康和生活质量。虽然我们的研究提供了一种可能改善TNBC预后的天然替代疗法,但未来对其治疗效果的验证需要大规模、长期的临床试验。

临床注册号

注册网站:www.chictr.org.cn,注册日期:2018年1月19日,注册号:ChiCTR1800014535。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ac9/11149640/fe129bf05e99/BCTT-16-289-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验